This was supposed to be Jack Johnson�s somber and
Thursday 4 September 2008
Monday 25 August 2008
Alternative Vaccine Strategy Shows Promise In Prostate Cancer Patients
�New research indicates that giving patients a continuous low lucy in the sky with diamonds of an immune system booster, a method known as metronomic dosing, as part of a healing prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side of meat effects than the more than common dosing method, which is non well tolerated by many patients. This study, lED by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.
The vaccine put-upon in this study is designed to stimulate an immune response against prostate-specific antigen (PSA), a protein produced by the prostate that is often establish at elevated levels in the blood of workforce who have prostate cancer and some non-cancerous prostate conditions. In the subject area, researchers examined the side effects and immune responses of patients treated with a three-pronged approach: the vaccine, radiation therapy, and an alternative dosing regimen of an immune system booster, interleukin-2 (IL-2). The patients all had localized prostate cancer the Crab, had not undergone surgery to remove the prostate, and were candidates for radiation therapy as their primary form of treatment.
"Developing an alternative method of administering vaccine therapy that is well tolerated by most patients and produces similar immune responses to standard methods crataegus oxycantha help farther the development of vaccine therapies for prostate cancer the Crab," said James L. Gulley, M.D., Ph.D., of NCI's Center for Cancer Research.
Therapeutic cancer vaccines ar designed to treat cancer by stimulating the immune system to attack tumor cells without harming normal cells. Several proteins, including PSA, are overexpressed, or produced in excess amounts, by cancer cells and have shown potential to serve as triggers in initiating immune responses. These findings have led to the exploitation of malignant neoplastic disease vaccines that target these proteins. The proteins ar also known as tumor-associated antigens. To heighten the body's natural defenses, immune system boosters, such as IL-2, ar often tending with the vaccines. IL-2 administration, however, is oftentimes associated with substantial face effects, including fatigue and high line sugar.
In a premature study involving the same prostate cancer vaccine, IL-2 was granted to 19 patients daily for cinque days during each 28-day vaccine intervention cycle, and a tumid majority of the patients had to have the dose of IL-2 reduced or discontinued, primarily because of fatigue.
In this new bailiwick, the researchers sought to decrease the side personal effects associated with IL-2. To do this, the squad treated 18 patients with the vaccinum and radiation syndrome therapy, just with depress doses of IL-2 apt over a longer period of time. The patients received the same amount amount of IL-2 as in the previous sketch, but it was administered in smaller daily doses for 14 days of each 28-day treatment hz.
With metronomic dosing, less than a quarter of the patients had side of meat effects that required their dose of IL-2 to be reduced.
The research team also found that metronomic dosing of IL-2 produced personal effects on immune cell populations and immune responses that were standardised to those observed previously with the standard dosing method. Five of eight evaluated patients had at least a three-fold gain in immune cells that were directed against PSA. The researchers also noted that, similar to the standard dosing method, metronomic dosing of IL-2 induced immune responses against early prostate cancer antigens in some patients.
"Based on safety and feasibility, metronomic dosing appears to be superior to standard dosing and governance," said Gulley. "More research is needed to measure the efficaciousness of this dosing method in treating prostate malignant neoplastic disease."
For more than information on Dr. Gulley's research, please go here.
For more information about cancer, please visit the NCI site at hTTP://www.cancer.gov, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal government agency for conducting and encouraging basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information virtually NIH and its programs, visit hypertext transfer protocol://www.national Institutes of Health.gov.
Reference
Lechleider RJ, Arlen PM, Tsang K, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, and Gulley JL. Safety and immunologic response of a viral vaccinum to PSA in combination with radiation therapy when metronomic-dose IL-2 is used as an adjuvant. Clinical Cancer Research. August 15, 2008.
Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang K, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, and Dahut W. Combining a recombinant cancer vaccine with standard unequivocal radiotherapy in patients with localized prostate cancer. Clinical Cancer Research. 2005;11:3353-62.
http://www.nih.gov
More info
The vaccine put-upon in this study is designed to stimulate an immune response against prostate-specific antigen (PSA), a protein produced by the prostate that is often establish at elevated levels in the blood of workforce who have prostate cancer and some non-cancerous prostate conditions. In the subject area, researchers examined the side effects and immune responses of patients treated with a three-pronged approach: the vaccine, radiation therapy, and an alternative dosing regimen of an immune system booster, interleukin-2 (IL-2). The patients all had localized prostate cancer the Crab, had not undergone surgery to remove the prostate, and were candidates for radiation therapy as their primary form of treatment.
"Developing an alternative method of administering vaccine therapy that is well tolerated by most patients and produces similar immune responses to standard methods crataegus oxycantha help farther the development of vaccine therapies for prostate cancer the Crab," said James L. Gulley, M.D., Ph.D., of NCI's Center for Cancer Research.
Therapeutic cancer vaccines ar designed to treat cancer by stimulating the immune system to attack tumor cells without harming normal cells. Several proteins, including PSA, are overexpressed, or produced in excess amounts, by cancer cells and have shown potential to serve as triggers in initiating immune responses. These findings have led to the exploitation of malignant neoplastic disease vaccines that target these proteins. The proteins ar also known as tumor-associated antigens. To heighten the body's natural defenses, immune system boosters, such as IL-2, ar often tending with the vaccines. IL-2 administration, however, is oftentimes associated with substantial face effects, including fatigue and high line sugar.
In a premature study involving the same prostate cancer vaccine, IL-2 was granted to 19 patients daily for cinque days during each 28-day vaccine intervention cycle, and a tumid majority of the patients had to have the dose of IL-2 reduced or discontinued, primarily because of fatigue.
In this new bailiwick, the researchers sought to decrease the side personal effects associated with IL-2. To do this, the squad treated 18 patients with the vaccinum and radiation syndrome therapy, just with depress doses of IL-2 apt over a longer period of time. The patients received the same amount amount of IL-2 as in the previous sketch, but it was administered in smaller daily doses for 14 days of each 28-day treatment hz.
With metronomic dosing, less than a quarter of the patients had side of meat effects that required their dose of IL-2 to be reduced.
The research team also found that metronomic dosing of IL-2 produced personal effects on immune cell populations and immune responses that were standardised to those observed previously with the standard dosing method. Five of eight evaluated patients had at least a three-fold gain in immune cells that were directed against PSA. The researchers also noted that, similar to the standard dosing method, metronomic dosing of IL-2 induced immune responses against early prostate cancer antigens in some patients.
"Based on safety and feasibility, metronomic dosing appears to be superior to standard dosing and governance," said Gulley. "More research is needed to measure the efficaciousness of this dosing method in treating prostate malignant neoplastic disease."
For more than information on Dr. Gulley's research, please go here.
For more information about cancer, please visit the NCI site at hTTP://www.cancer.gov, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal government agency for conducting and encouraging basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information virtually NIH and its programs, visit hypertext transfer protocol://www.national Institutes of Health.gov.
Reference
Lechleider RJ, Arlen PM, Tsang K, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, and Gulley JL. Safety and immunologic response of a viral vaccinum to PSA in combination with radiation therapy when metronomic-dose IL-2 is used as an adjuvant. Clinical Cancer Research. August 15, 2008.
Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang K, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, and Dahut W. Combining a recombinant cancer vaccine with standard unequivocal radiotherapy in patients with localized prostate cancer. Clinical Cancer Research. 2005;11:3353-62.
http://www.nih.gov
More info
Thursday 7 August 2008
Lotus Eaters
Artist: Lotus Eaters
Genre(s):
Ambient
Discography:
Mind Control for Infants
Year: 2002
Tracks: 6
Four Demonstrations 07.01
Year: 2001
Tracks: 4
Alienist On A Pale Horse Vinyl
Year: 2001
Tracks: 4
Liverpool, England's the Lotus Eaters were mistakenly included in the New Romantic drift when they number one appeared. However, although Peter Coyle (vocals), Jeremy Kelly (
Friday 27 June 2008
Moody hues at Playboy Jazz Festival
30th anniversary fest set for this weekend
If jazz had a Mount Rushmore, James Moody's face would be right up there with Charlie Parker and Dizzy Gillespie.
Maybe the next best thing -- aside from his live performance Saturday at the Playboy Jazz Festival -- is YouTube, where you can catch the great saxophonist as a member of Dizzy's first big band, back in the 1940s.
"If I'd have known what it was, I probably would have fainted with all that stuff," Moody likes to say of his stint with the source of the 20th century's greatest musical revolution.
" 'Cause when I joined the band, (Thelonious) Monk was the piano player and Klook was the drummer -- Kenny Clarke -- and Bags (Milt Jackson) was there, too." Not to mention such original gangsters as Miles Davis, Ray Brown and John Lewis.
Moody, 83, speaks today as he did when he was first recorded 60 years ago on the big band's "Emanon." This was not a health food store but a screaming blues track with breathtaking sarcastic breaks from Gillespie's horn, an inexorable groove from Ray Brown, the bassist, and a climactic passage reserved for Moody after Dizzy finishes.
Patrons of the 30th anniversary Playboy Jazz Festival will feel Moody's undiminished power when he appears with Roy Hargrove at the Hollywood Bowl. They can compare his live performance with the "Emanon" track, 99 cents on iTunes. The witty, emblematic opening; the bottomless resources; the unflagging swing; and the discreetly blasting climax -- his whole thing is there, and it has never run down.
On Saturday, Moody might favor MC Bill Cosby, his longtime friend, with a performance of the immortal "Moody's Mood for Love." He enthralled a Bowl audience last year when he and Roberta Gambarini combined the classic hit number with a deft comic routine.
Does he enjoy doing such things?
"Well, it depends," he said. "I enjoy playing music. I like to play music first, I mean that's what it is.
"I don't even like the comedy bit thing put in there because I'm really a musician. That's what I wanna do."
Does he feel that the long-popular number has overshadowed his other work?
"Well, I did that in 1949 in Stockholm, Sweden. That is when I did that." He would say no more on the topic.
So what would he and Hargrove play on Saturday?
"We'll play music," said the great James Moody, who is really a musician.
If jazz had a Mount Rushmore, James Moody's face would be right up there with Charlie Parker and Dizzy Gillespie.
Maybe the next best thing -- aside from his live performance Saturday at the Playboy Jazz Festival -- is YouTube, where you can catch the great saxophonist as a member of Dizzy's first big band, back in the 1940s.
"If I'd have known what it was, I probably would have fainted with all that stuff," Moody likes to say of his stint with the source of the 20th century's greatest musical revolution.
" 'Cause when I joined the band, (Thelonious) Monk was the piano player and Klook was the drummer -- Kenny Clarke -- and Bags (Milt Jackson) was there, too." Not to mention such original gangsters as Miles Davis, Ray Brown and John Lewis.
Moody, 83, speaks today as he did when he was first recorded 60 years ago on the big band's "Emanon." This was not a health food store but a screaming blues track with breathtaking sarcastic breaks from Gillespie's horn, an inexorable groove from Ray Brown, the bassist, and a climactic passage reserved for Moody after Dizzy finishes.
Patrons of the 30th anniversary Playboy Jazz Festival will feel Moody's undiminished power when he appears with Roy Hargrove at the Hollywood Bowl. They can compare his live performance with the "Emanon" track, 99 cents on iTunes. The witty, emblematic opening; the bottomless resources; the unflagging swing; and the discreetly blasting climax -- his whole thing is there, and it has never run down.
On Saturday, Moody might favor MC Bill Cosby, his longtime friend, with a performance of the immortal "Moody's Mood for Love." He enthralled a Bowl audience last year when he and Roberta Gambarini combined the classic hit number with a deft comic routine.
Does he enjoy doing such things?
"Well, it depends," he said. "I enjoy playing music. I like to play music first, I mean that's what it is.
"I don't even like the comedy bit thing put in there because I'm really a musician. That's what I wanna do."
Does he feel that the long-popular number has overshadowed his other work?
"Well, I did that in 1949 in Stockholm, Sweden. That is when I did that." He would say no more on the topic.
So what would he and Hargrove play on Saturday?
"We'll play music," said the great James Moody, who is really a musician.
Monday 23 June 2008
Kooks: 'Arctics are dead in the US'
The Kooks frontman Luke Pritchard has continued his war of words with the Arctic Monkeys by declaring their US career "dead".
Pritchard, who allegedly kicked Arctics frontman Alex Turner in the face, said the Kooks will be more successful in the US than their rivals.
He told The Sun: "It's really going great over there [in the US]. Radio is really picking up on the album.
"Arctic Monkeys have just died over there. They were huge for their first album but it hasn't happened with the second one."
See Also
Pritchard, who allegedly kicked Arctics frontman Alex Turner in the face, said the Kooks will be more successful in the US than their rivals.
He told The Sun: "It's really going great over there [in the US]. Radio is really picking up on the album.
"Arctic Monkeys have just died over there. They were huge for their first album but it hasn't happened with the second one."
See Also
Sunday 15 June 2008
Panteon Rococo
Artist: Panteon Rococo
Genre(s):
Latin
Discography:
Companeros
Year:
Tracks: 15
A La Izquierda De La Tierra
Year:
Tracks: 14
Latin rock band from Mexico Panteón Rococó was formed in the mid-'90s, transcription its first EP, called Pa' Mi Negra, in 1997. The undermentioned year, the group participated in a double-album called Eskuela De Baile, tributary with two of its original songs, "L'America" and "Curame." A alike compiling called Puro Eskañol came a year later, including Panteón Rococó's "Borracho." In 1999, the ten-piece Latin ska and reggae band was awarded at an event known as Skalaria for being the Best Local Ska Performer. In October of that same year, Panteón Rococó released its debut album, A La Izquierda De La Tierra.
Wednesday 11 June 2008
The Headhunters
Artist: The Headhunters
Genre(s):
Other
Discography:
Return of the Headhunters!
Year: 2005
Tracks: 10
Double success for Take That at the Brits
Subscribe to:
Posts (Atom)